The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Trial watch: Chemotherapy with immunogenic cell death inducers
Open accessAbstract
Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs, including conventional chemotherapeutics as well as targeted anticancer agents, originates (at least in part) from their ability to elicit a novel or reinstate a pre-existing tumor-specific immune response. One of the mechanisms whereby chemotherapy can stimulate the immune system to recognize and destroy malignant cells is commonly known as immunogenic cell death (ICD). Cancer cells succumbing to ICD are de facto converted into an anticancer vaccine and as such elicit an adaptive immune response. Several common chemotherapeutics share the ability of triggering ICD, as demonstrated in vaccination experiments relying on immunocompetent mice and syngeneic cancer cells. A large number of ongoing clinical trials involve such ICD inducers, often (but not always) as they are part of the gold standard therapeutic approach against specific neoplasms. In this Trial Watch, we summarize the latest advances on the use of cyclophosphamide, doxorubicin, epirubicin, oxaliplatin, and mitoxantrone in cancer patients, discussing high-impact studies that have been published during the last 13 months as well as clinical trials that have been initiated in the same period to assess the antineoplastic profile of these immunogenic drugs as off-label therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 3×
“On the other hand, breast carcinoma patients bearing loss-of-function polymorphisms in TLR4 and P2RX7 have been shown to relapse more quickly upon anthracycline-based chemotherapy and radiotherapy than control patients bearing wild-type polymorphisms.(11,15) As it stands, the capacity of a given chemotherapeutic agent…”
BackgroundSelf-citationMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Self-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421
Self-citationMolecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382
Self-citationCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Self-citationIdentification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
Bang, Y.-J., Kim, Y.-W., Yang, H.-K., Chung, H. C., Park, Y.-K., Lee, K. H., Lee, K.-W., Kim, Y. H., Noh, S.-I., Cho, J. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,705
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Self-citationAutophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Self-citationLee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Self-citationWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Self-citationImmunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Self-citationRoles of heat-shock proteins in innate and adaptive immunity.
Srivastava, P. (2002) · Nature reviews. Immunology · doi:10.1038/nri749 · Cited by 1,069
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
Self-citationHumanized mice for immune system investigation: progress, promise and challenges
Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., & Greiner, D. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3311 · Cited by 979
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Self-citationRole of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Self-citationCell death modalities: classification and pathophysiological implications
Galluzzi, L., Maiuri, M. C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402148 · Cited by 832 · cited 1×
“The long-standing notion that apoptosis would invariably constitute an immunologically silent (and hence would fail to activate the immune system), if not a tolerogenic (and hence would actively suppress immune responses), cell death modality has recently been invalidated.(1,2) Thus, at least in selected circumstances…”
BackgroundSelf-citationThe tumour microenvironment as a target for chemoprevention
Albini, A., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2067 · Cited by 823
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
Mitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733
Self-citationWaddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F. C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., Ferry, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70096-2 · Cited by 725
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Self-citationMa, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Self-citationEpothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 685
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Self-citationInflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
Self-citationMolecular mechanisms of ATP secretion during immunogenic cell death
Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Métivier, D., Galluzzi, L., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.75 · Cited by 563
Self-citationDecoding Cell Death Signals in Inflammation and Immunity
Zitvogel, L., Kepp, O., & Kroemer, G. (2010) · Cell · doi:10.1016/j.cell.2010.02.015 · Cited by 558 · cited 1×
“Thus, at least in selected circumstances, cancer cells die while emitting a spatiotemporally defined combination of signals that results in the activation of tumorspecific cognate immune responses.(3,4) The signals that have been associated with the productive perception of immunogenic cell death (ICD) by the immune s…”
BackgroundSelf-citationPeyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J.-F., Castaigne, S., Coiffier, B., Haioun, C., Bologna, S., Fitoussi, O., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70069-9 · Cited by 553
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y., & Hu, X. (2011) · Oncogene · doi:10.1038/onc.2011.137 · Cited by 512
Kowalski, R. J., Giannakakou, P., & Hamel, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2534 · Cited by 511
Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B. V., Larratt, L., Geisler, C. H., Montillo, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4556 · Cited by 480
Lee, J., Park, S. H., Chang, H.-M., Kim, J. S., Choi, H. J., Lee, M. A., Chang, J. S., Jeung, H. C., Kang, J. H., Lee, H. W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70301-1 · Cited by 478
Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., & Vile, R. G. (1998) · Nature Medicine · doi:10.1038/nm0598-581 · Cited by 445
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Self-citationCardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
Self-citationEffect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells.
Momparler, R. L., Karon, M. R., Siegel, S. E., & Avila, F. (1976) · PubMed · Cited by 423
Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Self-citationCastellino, F., Boucher, P. E., Eichelberg, K., Mayhew, M., Rothman, J. E., Houghton, A. N., & Germain, R. N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.11.1957 · Cited by 404
Synthesis of epothilones A and B in solid and solution phase
Nicolaou, K. C., Winssinger, N., Pastor, J., Ninkovic, S., Sarabia, F., He, Y., Vourloumis, D., Yang, Z., Li, T., Giannakakou, P., et al. (1997) · Nature · doi:10.1038/387268a0 · Cited by 400
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388
Arndt, C. A. S., Stoner, J. A., Hawkins, D. S., Rodeberg, D. A., Hayes-Jordan, A. A., Paidas, C. N., Parham, D. M., Teot, L. A., Wharam, M. D., Breneman, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3768 · Cited by 380
Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity
Aymeric, L., Apetoh, L., Ghiringhelli, F., Tesniere, A., Martins, I., Kroemer, G., Smyth, M. J., & Zitvogel, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3566 · Cited by 380
Self-citationSchiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344
Self-citationTargeting the Tumor Microenvironment for Cancer Therapy
Sounni, N. E., & Noel, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.185363 · Cited by 344
Mesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A. V., Ancliff, P., Morgan, M., Masurekar, A., Goulden, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62002-8 · Cited by 330
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305
Zhu, A. X., Meyerhardt, J. A., Blaszkowsky, L. S., Kambadakone, A. R., Muzikansky, A., Zheng, H., Clark, J. W., Abrams, T. A., Chan, J. A., Enzinger, P. C., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70333-x · Cited by 303
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Self-citationImmunomonitoring and prognostic relevance of neutrophils in clinical trials
Donskov, F. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.001 · Cited by 293
Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., Haque, W., Hobbs, B. D., Krishnan, S., Fleming, J. B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8038 · Cited by 288
Chemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
Self-citationPlasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Inducers of immunogenic cancer cell death
Dudek, A. M., Garg, A. D., Krysko, D. V., De Ruysscher, D., & Agostinis, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.005 · Cited by 250
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Self-citationGruenberger, B., Schueller, J., Heubrandtner, U., Wrba, F., Tamandl, D., Kaczirek, K., Roka, R., Freimann-Pircher, S., & Gruenberger, T. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70247-3 · Cited by 247
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20931 · Cited by 244
Self-citationMamot, C., Ritschard, R., Wicki, A., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., & Rochlitz, C. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70476-x · Cited by 244
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 235
Self-citationBeverly Raney, R., Walterhouse, D. O., Meza, J. L., Andrassy, R. J., Breneman, J. C., Crist, W. M., Maurer, H. M., Meyer, W. H., Parham, D. M., & Anderson, J. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4469 · Cited by 230
Danger signalling during cancer cell death: origins, plasticity and regulation
Garg, A. D., Martin, S., Golab, J., & Agostinis, P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.48 · Cited by 226
Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., Urata, Y., Okazaki, T., Marumoto, T., Takahashi, A., Takayama, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3185 · Cited by 222
Berndtsson, M., Hägg, M., Panaretakis, T., Havelka, A. M., Shoshan, M. C., & Linder, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22132 · Cited by 215
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212
Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E., Morselli, E., Senovilla, L., Araujo, N., Pinna, G., Larochette, N., Zamzami, N., et al. (2008) · Oncogene · doi:10.1038/onc.2008.63 · Cited by 208
Self-citationKummar, S., Ji, J., Morgan, R., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D., Kiesel, B., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 199
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
Self-citationChemotherapy and radiotherapy: Cryptic anticancer vaccines
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 193
Self-citationMoebus, V., Jackisch, C., Lueck, H.-J., du Bois, A., Thomssen, C., Kurbacher, C., Kuhn, W., Nitz, U., Schneeweiss, A., Huober, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7643 · Cited by 192
Galsky, M. D., Small, E. J., Oh, W. K., Chen, I., Smith, D. C., Colevas, A. D., Martone, L., Curley, T., DeLaCruz, A., Scher, H. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.042 · Cited by 189
Kim, E. J., Ben‐Josef, E., Herman, J. M., Bekaii‐Saab, T., Dawson, L. A., Griffith, K. A., Francis, I. R., Greenson, J. K., Simeone, D. M., Lawrence, T. S., et al. (2013) · Cancer · doi:10.1002/cncr.28117 · Cited by 182
Galluzzi, L., Berghe, T. V., Vanlangenakker, N., Büttner, S., Eisenberg, T., Vandenabeele, P., Madeo, F., & Kroemer, G. (2011) · International review of cytology · doi:10.1016/b978-0-12-386039-2.00001-8 · Cited by 181
Self-citationHecht, J. R., Trarbach, T., Hainsworth, J. D., Major, P., Jäger, E., Wolff, R. A., Lloyd-Salvant, K., Bodoky, G., Pendergrass, K., Berg, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4496 · Cited by 178
Liu, X., Shi, Y., Maag, D. X., Palma, J. P., Patterson, M. J., Ellis, P. A., Surber, B. W., Ready, D. B., Soni, N. B., Ladror, U. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1973 · Cited by 174
Trial watch: Dendritic cell-based interventions for cancer therapy
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 173
Self-citationTrial watch: Peptide vaccines in cancer therapy
Vacchelli, E., Martins, I., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22428 · Cited by 171
Self-citationPere, H., Montier, Y., Bayry, J., Quintin-Colonna, F., Merillon, N., Dransart, E., Badoual, C., Gey, A., Ravel, P., Marcheteau, E., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329656 · Cited by 166
Self-citationBuglio, D., Georgakis, G. V., Hanabuchi, S., Arima, K., Khaskhely, N. M., Liu, Y.-J., & Younes, A. (2008) · Blood · doi:10.1182/blood-2008-01-133769 · Cited by 161
Ducreux, M. P., Malka, D., Mendiboure, J., Etienne, P.-L., Texereau, P., Auby, D., Rougier, P. R., Gasmi, M., Castaing, M., Abbas, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70199-1 · Cited by 159
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review
Stordal, B., Pavlakis, N., & Davey, R. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.009 · Cited by 159
Sondak, V. K., Smalley, K. S. M., Kudchadkar, R. R., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3463 · Cited by 158
Trial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 152
Self-citationBurnell, M. J., Levine, M. N., Chapman, J. W., Bramwell, V. H. C., Gelmon, K. A., Walley, B. A., Vandenberg, T. A., Chalchal, H. I., Albain, K. S., Perez, E. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1077 · Cited by 151
Zappasodi, R., Pupa, S. M., Ghedini, G. C., Bongarzone, I., Magni, M., Cabras, A. D., Colombo, M. P., Carlo‐Stella, C., Gianni, A. M., & Nicola, M. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1825 · Cited by 150
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Catani, J. P. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 149
Self-citationWeiner, H. L., & Cohen, J. A. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms790oa · Cited by 148
Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Li, Y., Wang, L., Pang, P., Cui, Z.-H., Aung, S., Haley, D. P., Fox, B. A., Urba, W. J., & Hu, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0951 · Cited by 145
Abscopal Effect in a Patient with Melanoma
Hiniker, S. M., Chen, D. S., & Knox, S. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1203984 · Cited by 143
Enlightening the impact of immunogenic cell death in photodynamic cancer therapy
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.2 · Cited by 142
Self-citationde La Motte Rouge, T., Galluzzi, L., Olaussen, K. A., Zermati, Y., Tasdemir, E., Robert, T., Ripoche, H., Lazar, V., Dessen, P., Harper, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0538 · Cited by 141
Self-citationTrial watch: Cardiac glycosides and cancer therapy
Menger, L., Vacchelli, E., Kepp, O., Eggermont, A. M. M., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23082 · Cited by 141
Self-citationChen, H., Wang, P.-H., Chen, S.-S., Wen, C.-C., Chen, Y., Yang, W., & Yang, N. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1258-9 · Cited by 141
Autophagy-dependent ATP release from dying cells via lysosomal exocytosis
Wang, Y., Martins, I., Ma, Y., Kepp, O., Galluzzi, L., & Kroemer, G. (2013) · Autophagy · doi:10.4161/auto.25873 · Cited by 137
Self-citationNakahara, T., Uchi, H., Lesokhin, A. M., Avogadri, F., Rizzuto, G. A., Hirschhorn-Cymerman, D., Panageas, K. S., Merghoub, T., Wolchok, J. D., & Houghton, A. N. (2010) · Blood · doi:10.1182/blood-2009-11-251231 · Cited by 134
Slingluff, C. L., Petroni, G. R., Chianese‐Bullock, K. A., Smolkin, M. E., Ross, M. I., Haas, N. B., von Mehren, M., & Grosh, W. W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8053 · Cited by 132
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Galluzzi, L., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.2.19026 · Cited by 132
Self-citationVansteenkiste, J., Lara, P. N., Chevalier, T. L., Breton, J.-L., Bonomi, P., Sandler, A. B., Socinski, M. A., Delbaldo, C., McHenry, B. M., Lebwohl, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7097 · Cited by 130
Greten, T. F., Ormandy, L. A., Fikuart, A., Höchst, B., Henschen, S., Hörning, M., Manns, M. P., & Korangy, F. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181bb499f · Cited by 129
Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
Garg, A. D., Dudek, A. M., & Agostinis, P. (2013) · BioFactors · doi:10.1002/biof.1125 · Cited by 128
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Galluzzi, L., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 126
Self-citationMoosmann, N., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Hass, H. G., Dietzfelbinger, H., Oruzio, D. V., Klein, S., Zellmann, K., Decker, T. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1936 · Cited by 126
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Boehrer, S., Adès, L., Braun, T., Galluzzi, L., Grosjean, J., Fabre, C., Roux, G. L., Gardin, C., Martin, A., de Botton, S., et al. (2007) · Blood · doi:10.1182/blood-2007-07-100362 · Cited by 124
Self-citationKorbelik, M., Zhang, W., & Merchant, S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1047-x · Cited by 123
Colombo, N., Kutarska, E., Dimopoulos, M. A., Bae, D., Rzepka-Górska, I., Bidziński, M., Scambia, G., Engelholm, S. A., Joly, F., Weber, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8082 · Cited by 122
Targeting p53 to mitochondria for cancer therapy
Galluzzi, L., Morselli, E., Kepp, O., Tajeddine, N., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6222 · Cited by 120
Self-citationChu, C., Boyer, J., Schullery, D. S., Gimotty, P. A., Gamerman, V., BENDER, J. G., Levine, B. L., Coukos, G., Rubin, S. C., Morgan, M. A., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1081-8 · Cited by 118
The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
Bindea, G., Mlecnik, B., Fridman, W. H., & Galon, J. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0264-x · Cited by 113
Self-citationAnticancer activity of cardiac glycosides
Kepp, O., Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Sukkurwala, A. Q., Michaud, M., Galluzzi, L., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.21684 · Cited by 111
Self-citationTrial Watch: DNA vaccines for cancer therapy
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28185 · Cited by 110
Self-citationHoffmann, J., Vitale, I., Buchmann, B., Galluzzi, L., Schwede, W., Senovilla, L., Skuballa, W., Vivet, S., Lichtner, R. B., Vicencio, J. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0237 · Cited by 110
Self-citationLow Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study
Lord, R., Nair, S., Schache, A. G., Spicer, J. F., Somaihah, N., Khoo, V. S., & Pandha, H. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.143 · Cited by 110
Ma, Y., Adjemian, S., Yang, H., Catani, J. P. P., Hannani, D., Martins, I., Michaud, M., Kepp, O., Sukkurwala, A. Q., Vacchelli, E., et al. (2013) · OncoImmunology · doi:10.4161/onci.24568 · Cited by 104
Self-citationManagement of worsening multiple sclerosis with mitoxantrone: A review
Fox, E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.013 · Cited by 102
Robak, T., Jamroziak, K., Góra‐Tybor, J., Stella-Holowiecka, B. M., Konopka, L., Ceglarek, B. B., Warzocha, K., Seferyńska, I., Piszcz, J. A., Całbecka, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9630 · Cited by 102
Trial watch: Monoclonal antibodies in cancer therapy
Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 101
Self-citationTrial Watch: Anticancer radioimmunotherapy
Vacchelli, E., Vitale, I., Tartour, É., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 100
Self-citationEngel, J. B., Emons, G., Pinski, J., & Schally, A. V. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685128 · Cited by 96
Luke, J. J., D'Adamo, D. R., Dickson, M. A., Keohan, M. L., Carvajal, R. D., Maki, R. G., de Stanchina, E., Musi, E., Singer, S., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3203 · Cited by 95
Ludgate, C. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1175 · Cited by 93
Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91
Gourdier, I., Crabbé, L., Andréau, K., Pau, B., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208047 · Cited by 91
Self-citationInduction of Foxp3+ regulatory T cells with histone deacetylase inhibitors
Lucas, J. L., Mirshahpanah, P., Haas-Stapleton, E. J., Asadullah, K., Zollner, T. M., & Numerof, R. P. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.03.004 · Cited by 91
How I treat patients with myelodysplastic syndromes
Stone, R. M. (2009) · Blood · doi:10.1182/blood-2008-09-038935 · Cited by 90
Goldberg, R. M., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1728 · Cited by 90
Moroney, J. W., Fu, S., Moulder, S. L., Falchook, G. S., Helgason, T., Levenback, C., Hong, D. S., Naing, A., Wheler, J. J., & Kurzrock, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1158 · Cited by 87
Ellis, L. M., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1727 · Cited by 87
Siefker-Radtke, A. O., Dinney, C. P., Shen, Y., Williams, D. L., Kamat, A. M., Grossman, H. B., & Millikan, R. E. (2012) · Cancer · doi:10.1002/cncr.27751 · Cited by 84
Stoetzer, O., Fersching, D., Salat, C., Steinkohl, O., Gabka, C., Hamann, U., Braun, M., Feller, A., Heinemann, V., Siegele, B., et al. (2013) · Tumor Biology · doi:10.1007/s13277-012-0513-1 · Cited by 82
Trial Watch: Adoptive cell transfer immunotherapy
Galluzzi, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19549 · Cited by 81
Self-citationMartín-Richard, M., Gallego, R., Pericay, C., García‐Foncillas, J., Queralt, B., Casado, E., Barriuso, J., Iranzo, V., Juez, I., Visa, L., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0020-2 · Cited by 80
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24238 · Cited by 79
Self-citationde Vries, I. J. M., Castelli, C., Huygens, C., Jacobs, J. F. M., Stockis, J., Schuler‐Thurner, B., Adema, G. J., Punt, C. J. A., Rivoltini, L., Schuler, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2227 · Cited by 78
Navid, F., Baker, S. D., McCarville, M. B., Stewart, C. F., Billups, C. A., Wu, J., Davidoff, A. M., Spunt, S. L., Furman, W. L., McGregor, L. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1897 · Cited by 75
Fahmueller, Y. N., Nagel, D., Hoffmann, R., Tatsch, K., Jakobs, T., Stieber, P., & Holdenrieder, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.27894 · Cited by 71
Wittwer, C., Boeck, S., Heinemann, V., Haas, M., Stieber, P., Nagel, D., & Holdenrieder, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28294 · Cited by 68
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 63
Self-citationLow dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma
Šanović, R., Verwanger, T., Hartl, A. J., et al. (2011) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2011.04.003 · Cited by 63
Immunosurveillance as a regulator of tissue homeostasis
Senovilla, L., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.06.005 · Cited by 62
Self-citationKharaziha, P., Rodriguez, P. Q., Li, Q., Rundqvist, H., Björklund, A.-C., Augsten, M., Ullén, A., Egevad, L., Wiklund, P. N., Nilsson, S. F., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.1 · Cited by 59
Self-citationEffective targeting of the tumor microenvironment for cancer therapy.
Jiang, P., Li, X., Thompson, C. B., Huang, Z., Araiza, F., Osgood, R. J., Wei, G., Feldmann, M., Frost, G. I., & Shepard, H. M. (2012) · PubMed · Cited by 58
Allavena, P., Germano, G., Belgiovine, C., D’Incalci, M., & Mantovani, A. (2013) · OncoImmunology · doi:10.4161/onci.24614 · Cited by 55
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy
Kroemer, G., & Zitvogel, L. (2012) · OncoImmunology · doi:10.4161/onci.20074 · Cited by 53
Self-citationInhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells
Wang, K., Bodempudi, V., Liu, Z., Borrego-Diaz, E., Yamoutpoor, F., Meyer, A., Woo, R. A., Pan, W., Dudek, A. Z., Olyaee, M. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033214 · Cited by 52
Kharaziha, P., Raeve, H. D., Fristedt, C., Li, Q., Gruber, A., Johnsson, P., Kokaraki, G., Panzar, M., Laane, E., Österborg, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0658 · Cited by 52
Park, I., Ryu, M., Choi, Y. H., Kang, H. J., Yook, J. H., Park, Y. S., Kim, H. J., Jung, H., Lee, G. H., Kim, K. C., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2257-z · Cited by 51
Kudawara, I., Aoki, Y., Ueda, T., Araki, N., Naka, N., Nakanishi, H., Matsumine, A., Ieguchi, M., Mori, S., Myoui, A., et al. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000055 · Cited by 50
Immune effects of 5-fluorouracil
Ghiringhelli, F., Bruchard, M., & Apétoh, L. (2013) · OncoImmunology · doi:10.4161/onci.23139 · Cited by 49
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Kim, R. D. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70237-0 · Cited by 48
Qayum, N., Im, J. H., Stratford, M. R. L., Bernhard, E. J., McKenna, W. G., & Muschel, R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1413 · Cited by 48
Kelley, R. K., Hwang, J. H., Magbanua, M. J. M., Watt, L., Beumer, J. H., Christner, S. M., Baruchel, S., Wu, B., Fong, L. H., Yeh, B. M., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.553 · Cited by 46
Pro-apoptotic signaling induced by photo-oxidative ER stress is amplified by Noxa, not Bim
Verfaillie, T., van Vliet, A. R., Garg, A. D., Dewaele, M., Rubio, N., Gupta, S., de Witte, P. A. M., Samali, A., & Agostinis, P. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.107 · Cited by 45
Connor, J. P., Cristea, M. C., Lewis, N. L., Lewis, L. D., Komarnitsky, P. B., Mattiacci, M. R., Felder, M. A. R., Stewart, S., Harter, J. M., Henslee-Downey, J. P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-20 · Cited by 43
Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer
Raez, L. E., Kobina, S., & Santos, E. S. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.003 · Cited by 42
Pollack, B. P. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18073 · Cited by 39
Camisaschi, C., Filipazzi, P., Tazzari, M., Casati, C., Beretta, V., Pilla, L., Patuzzo, R., Maurichi, A., Cova, A., Maio, M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1397-7 · Cited by 38
Atmaca, A., Al-Batran, S.-E., Werner, D., Pauligk, C., Güner, T., Koepke, A. K. E., Bernhard, H., Wenzel, T., Banat, A.-G., Brueck, P., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.555 · Cited by 37
Sonnemann, J., Greßmann, S., Becker, S., Wittig, S., Schmudde, M., & Beck, J. F. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1302-4 · Cited by 32
Patupilone in cancer treatment
Bystrický, B., & Chau, I. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.542148 · Cited by 31
Michielsen, A. J., Ryan, E. J., & O'Sullivan, J. N. (2012) · OncoImmunology · doi:10.4161/onci.21318 · Cited by 31
Cancer drugs better than taxol?
Cowden, C. J. (1997) · Nature · doi:10.1038/387238a0 · Cited by 28
Malvicini, M., Alaniz, L. D., Bayo, J., García, M. G., Piccioni, F., Fiore, E. J., Atorrasagasti, C., Aquino, J. B., Matar, P., & Mazzolini, G. D. (2012) · OncoImmunology · doi:10.4161/onci.20684 · Cited by 28
Cited by
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Self-citationMlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Self-citationThe Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Self-citation
Metadata
- Authors
- Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2013-03
- Volume
- 2
- Issue
- 3
- Pages
- e23510
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2031659092
- Cited by
- 265
- References
- 219
- FWCI
- 22.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.